about the pastOver the past 50 years, outcomes for people diagnosed with cancer have changed. In 1970, about half of the cancer patients in the United States were still alive five years later. For patients diagnosed in 2009, the figure was closer to 70%.1Journal of the National Cancer Institute; Surveillance, Epidemiology, and Outcomes Program; see also Hannah Ritchie's data visualization, Cancer Deaths Are Falling; Five-Year Survival Rates Are Rising”, Our World in Data, February 2019 4, ourworldindata.org ; Cancer facts and figures 2020, American Cancer Society, cancer.org.This shift in outcomes has been achieved through a combination of public health interventions (such as smoking education), improved healthcare (such as early detection), and new drug therapies. This triad has transformed some diagnoses that were once considered incurable into chronic conditions. For example, the mortality rate in most patients currently diagnosed with multiple myeloma or prostate cancer is related to diseases other than cancer. Additionally, oncology therapies accounted for $143 billion in branded drug sales in 2019, accounting for about 20% of global drug sales.2 Product Sales, EvaluatePharma® July 2020, Evaluate Ltd.Analysts agree that global oncology therapy sales are expected to reach $250 billion by 2024, with a strong compound annual growth rate (CAGR) of 12%.
However, there is still a lot to do. The five-year survival rate for pancreatic cancer, glioblastoma and non-small cell lung cancer (NSCLC, the most common form of lung cancer) remains below 50 percent in treated patients. These three cancers account for more than 250,000 new diagnoses each year in the United States alone.3 Cancer Statistical Facts, Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, seer.cancer.gov.Despite considerable, justified excitement about the use of PD-(L)14 Refers to PD-1 and PD-L1 therapies.In NSCLC, the response rate remains below 50%.
With 4 million new patients per year in China, there is an unmet need
Although representing China18% of the world cancer burden and more than 50% of patients with liver cancer, stomach cancer and esophageal cancer in my country.1 A detailed look at the Chinese oncology market in Managing China's Growing Oncology Burden, August 26, 2020.Despite improvements in healthcare infrastructure, large gaps remain: China has an average of 26 oncologists per million population compared to 60 per million in the US, and many patients are diagnosed with advanced disease.
Faced with this opportunity, both local and multinational pharmaceutical companies are making significant and growing investments in developing therapies for China. By 2025, 18 mechanisms of action are expected to be approved for NSCLC and 13 for HCC, up from six and three currently, respectively. We are also seeing the first global approvals for new treatments in China, such as BeiGene's approval of tislelizumab for Hodgkin's lymphoma by the National Medical Products Administration in December 2019. Approvals in China have historically been time-consuming, although the time span between these and worldwide launches decreased from 8.4 years in 2016 to 4.6 years in 2019. In this case, we would expect approvals to increase in China (these two therapies were developed both domestically and overseas).
In addition to its status as a major oncology market, China is also increasingly emerging as a source of innovation. Some drugs developed by Chinese biotechs have the potential to be world-firsts or best-in-class, such as Chi-Med's savolitinib, paving the way for affordable China-led innovation, as we saw in the PD-1 market. Innovent's PD-1 product was included in the national health insurance list in 2019, and the total annual treatment cost for non-Hodgkin lymphoma patients is 102,000 yuan (about US$14,600). It is not surprising that international companies are investing heavily in oncology R&D in China: AstraZeneca, Eli Lilly, Janssen and Roche have all established or expanded their R&D presence and partnerships in China over the past three years.
In addition, we found significant differences in results between regions. Five-year survival rates for non-Hodgkin's lymphoma (NHL) vary - 63% in Northern Europe to 50% in Eastern Europe - and 10-year survival rates for breast cancer - new EUROCARE 5 results show - 76% in Northern and Eastern Europe accounted for 65%.5 Has cancer care improved in Europe since the 1990s? : Latest results of the EUROCARE-5 study, European Cancer Congress, Vienna, Austria, 25-29. September 2015, eurocare.it.Although China still lags behind developed markets, performance has improved significantly; for example, the five-year overall survival rate for all cancers diagnosed in 2013 was estimated to be around 40%, compared to five years. The annual survival rate is about 30%.6Peter Baade et al., „Changes in cancer Survival in China 2003-15: A pooled Analysis of 17 population-based cancer registers“, The Lancet, mei 2018, Band 6, Nr. 5, Nr. 555- 67 Seiten, thelancet.com.Still, there is ample opportunity for China to bring further innovation to the 4 million patients diagnosed each year (see box “China's 4 million new patients each year, a major unmet need”).
Innovations in oncology are gaining momentum. While about eight years elapsed between the first treatment of HER2-positive patients in 1999 and the next treatment, the first PARP inhibitor hit the market in 2013 and the next was less than two years away. The next wave of innovation for patients is happening at an ever faster pace around the world. Dynamism and innovation are expected in immuno-oncology treatments, with more than 550 active cell and gene therapy agents in clinical development.
We examine the current state of the global oncology drug market to determine where to invest, where unmet need is greatest and where competition is fiercest. Our analysis also uncovers five disruptive trends that could change the strategic priorities of oncology pharmaceutical leaders - and potentially even the face of the oncology market itself.
Oncology is the largest drug therapy area in the world and is highly competitive
Advances in oncology have significantly improved patient outcomes (Figure 1). But with the heavy investment in oncology research and development, both academia and industry, experts agree that much more needs to be done. Oncology is a priority area announced by the top ten pharmaceutical companies, with an estimated 1,700 clinical compounds in development (approximately one-third of the global clinical pipeline across all therapeutic areas).7 compounds in clinical development (phase I-III), excluding reformulated and biosimilars, Pharmaprojects, 2019, pharmaintelligence.informa.com.For NSCLC, approximately 100 active phase III trials in the US represent approximately 75,000 patients. For ALL, about 25 studies required the enrollment of more than 32,000 patients into clinical trials - more than the number of people who were newly diagnosed in one year.8 Retrieved from Clinicaltrials.gov, October 24, 2019. Include interventional trials with one of the following enrollment statuses: enrolling, active, not enrolling, or invited to enroll.
In addition to extensive organic R&D by Big Pharma and numerous clinical-stage biotechs, we've also seen a spate of multi-billion dollar oncology acquisitions (e.g., Pfizer's $11 billion acquisition of Array BioPharma in 2019) and partnerships (including a $3 billion acquisition observed collaboration between AbbVie and Genmab on bispecific antibodies). Enthusiasm for oncology goals has resulted in a high contract premium. Over the past five years, the average oncology acquisition premium has been about 100% for deals valued at more than $5 billion.
However, if past trends repeat themselves, a fraction of these assets will shape future markets (Exhibit 2). The current success rate (from first human trial to commercial launch) in oncology is approximately 13%, with an average development time of 9.5 years.9 McKinsey based on an analysis of success rates of oncology development programs excluding reformulations and biosimilars from 2008 to 2018; Time to market based on median time to win based on oncology development programs excluding reformulations from 2010 to 2018. Formulations and biosimilars; see Pharma Projects, 2019, pharmaintelligence.informa.com.Post-launch results also vary wildly: Seven products valued at more than $5 billion accounted for 39% of sales in 2019, and more than half of products launched in the last five years are self-administered record a decline in sales at their peak. Generate over $500 million per year10 Product Sales Estimate, EvaluatePharma® July 2020, Evaluate Ltd.(Appendix 3). While the clinical pipeline is full of promising prospects, it is likely that only a small portion has sufficiently transformative benefit-risk profiles to drive ROI.
The oncology market encompasses many different indications
Although oncology is often grouped together as a single therapeutic area, it encompasses more than 20 different indications, with five of these indications accounting for the majority of current sales. In 2019, breast cancer, multiple myeloma, NSCLC, prostate cancer and NHL generated $90 billion in revenue (68% of the market). This number is expected to increase to US$141 billion (64% of the market) by 2024, primarily due to increasing sales of NSCLC PD(L)1.11Produktechattingen，EvaluatePharma® Juli 2020，Evaluate Ltd.While each of these five indications has significant morbidity and unmet need, sales correlate better with the presence of a handful of breakthrough therapies (Figure 4).
Global oncology therapy sales are expected to reach $250 billion by 2024.(Video) An Insider's Look: Innovations in Neuro-Oncology Research
In the commercial environment, most large pharmaceutical companies focus on synergistic subsets of indications with overlapping focuses and key opinion leader relationships. However, in a research and development setting, scientists do not know where new treatments work beyond their hypothesis. We therefore see that most players are exploring a broader range of indications by applying more “targeting” – the more indications they address, the more likely their approach is to result in a blockbuster product (Figure 5).
Oncology growth, strategic focus area status and potential focus areas are influenced by four overarching trends by indication and indication group:
- Growth potential in mature markets.In the short term, manufacturers are expected to continue their high market growth by expanding the geographic coverage and areas of application of these therapies, for example by switching to previous treatments in addition to surgery. While there remains an unmet need (in many cases, the five-year survival rate for patients with metastatic disease is less than 50%), standard of care has set a high bar and requires truly transformative therapies to gain approval and use. The main indications are multiple myeloma, HER2 and ER+ breast cancer, prostate cancer, renal cell carcinoma and lung cancer mediated by anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
- The patient's treatment effect continued to be poor.This indication group is the holy grail of oncology research and development and is characterized by poor patient outcomes (less than 15% five-year survival rate) and very high patient numbers (more than 30,000 new patients per year in the US). Currently, only limited therapies are available for these indications or response rates to existing therapies are poor. Therefore, any effective therapy would offer an opportunity to change the standard of care, reshape cancer at the therapeutic level, and be extremely attractive from a commercial perspective. The main indications are colorectal cancer, hepatocellular carcinoma, pancreatic cancer, non-ALK and non-EGFR NSCLC.
- There are large patient populations with unmet needs.A large group of cancers with significant unmet needs (five-year survival rates less than 30% in most cases) and sizeable patient populations—typically 5,000 to 30,000 new patients diagnosed in the US each year (Figure 6). Despite the relatively small unmet need for developing effective therapies, it is commercially attractive. In the absence of more innovative therapies, chemotherapy remains the standard of care for most patients. Key indications include soft tissue sarcomas, gastrointestinal stromal tumors and triple negative breast, small cell lung, ovarian, uterine and esophageal cancers.
- niche cancer.Manufacturers have the opportunity to respond to a large number of less common cancers that affect fewer than 5,000 people each year. While the unmet need for certain indications, e.g. B. glioblastoma, is very high, the smaller patient population requires a new approach to the development and commercialization of effective therapies. This approach could include site-independent approvals to group many niche cancer types or orphan drug approvals to allow rapid market entry. The main indications are T-cell carcinoma, thyroid carcinoma, glioma and glioblastoma.
Disruptive trends are expected to impact oncology in the years to come
Oncology is at the forefront of precision medicine: more than 160 tumor biomarkers were approved in 2019, and more than 90% of crucial research focused on molecular targets.
Despite the pharmaceutical industry's track record in oncology, there are still significant unmet needs that need to be addressed. Five trends that could revolutionize the already changing innovation landscape in oncology.
New cell and gene therapies
The last five years have been marked by a growing enthusiasm for new therapies, including cell therapies, viral vectors, RNA therapies and stem cell therapies. In oncology, two chimeric antigen receptor T-cell (CAR-T) therapies, Kymriah and Yescarta, have been approved for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) with unprecedented efficacy. While CAR-T sales are currently modest, hundreds of compounds are being tested and sales are projected to exceed $6 billion by 2024.12Vanessa M. Hubbard-Lucey, Jun Tang and Jia Xin Yu, "A Global Pipeline of Cancer Cell Therapies", Nature, 30 May 2019, nature.com.However, cell and gene therapies are wreaking havoc on current healthcare approaches as manufacturing and supply chain processes become more complex, particularly for autologous therapies. These therapies also have longer lead times and more sophisticated treatment regimens, and - since many have the potential for one-time cures - more complex market access considerations. asDepartment of Cell and Gene TherapyTo fulfill their promise, they willA fundamental change is requiredIn healthcare paradigms and business models, including delivery systems with economic incentives and access models that achieve and reward long-term benefits.
Precision medicine – getting the right drug to the right patient at the right time – is advancing at a rapid pace. Oncology is at the forefront of this trend: more than 160 tumor biomarkers were approved in 2019, and more than 90% of crucial research focused on molecular targets.13 Table of Pharmacogenomic Biomarkers in Drug Labeling, Food and Drug Administration, December 2019 update, fda.gov.As more therapies target subpopulations, driving the adoption of biomarker testing and patient mapping and discovery will be a key competitive advantage. For example, in addition to the three most common mutations in NSCLC (mutations associated with the ALK and KRAS genes and the EGFR protein), there are also a large number of less common mutations, each accounting for less than 3% of patients.14Dara L. Aisner et al., “Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: experiences from the Lung Cancer Mutation Consortium”, Journal of Thoracic Oncology, Vol. 10, No. 5, No. 768 – May 2015. 77, Japan Trade Organization . Tissue; Ethan Cerami et al., "Prospects for kinase fusions in cancer", Nature Communications, 10 September 2014, vol. 5, nature.com; Julie M. Batten et al., "ROS1 rearrangement defines unique molecular classes of lung cancer", Journal of Clinical Oncology, 10 March 2012, Vol. 30, No. 8, 863-70, ascopubs.org.Ways to increase test uptake can include working with test providers and governments, and promoting physician education. Once tested in patients, different approaches can improve treatment acceptance. This includes identifying prescribing potential based on electronic health records and engaging key stakeholders, such as patient advocacy groups, to better understand patient-physician relationships. journey in between. Additionally, as pharmaceutical companies develop therapies for smaller patient populations, exploring new clinical trials and business models will be crucial to ensure costs are reasonable for the potential patient population.
Accelerate the development schedule
As more pharmaceutical companies move into the field of oncology, competition for important targets has intensified. We estimate that nearly 80% of new clinical drugs target one marketed therapy or four or more clinical competitors.15 Pharmaceutical Articles | Informa December 2017. McKinsey analysis based on number of new assets tracked by MOA (based on primary objective), excluding new assets for which MOA was not disclosed; see Pharmaprojects, 2017, pharmaintelligence.informa.com.Increasing competition has shortened development cycles, with competing therapies entering the market soon after their initial commercial launch. To thrive in this environment, new development paradigms must be explored, including a greater emphasis on prior studies (as 54% of breakthrough asset approvals are based on Phase I or Phase II studies).16 Based on assets with breakthrough designations approved between 2013 and 2019, Breakthrough Therapies, Friends of Cancer Research, updated June 2020, focr.org.), site-independent approvals (e.g. Keytruda for MSI-H or dMMR mutations and Vitrakvi for NTRK mutations) and examining real-world evidence for the expansion of specific treatment indications (e.g. Ibrance for male breast cancer or ongoing Opdivo Study ATTRACTION-2). carried out).
Immuno-oncological combination therapy
Companies have increased investment in collaborative immuno-oncology research, with more than 200 mechanisms currently being investigated as joint PD-(L)1 or CTLA-4 partners, and immuno-oncology assets are estimated to account for about half of the top 10 the far However, widespread use of combination therapies complicates study design, especially when no combination partners are currently approved or the additional costs of a combination partner have to be covered for the clinical trial. At launch, these combination therapies are expected to result in higher treatment costs and may require new models to collaborate with payers and demonstrate cost-effectiveness.
new listing model
The changing development landscape requires pharmaceutical companies to fundamentally rethink how they deliver medicines to physicians and patients. Treatment modalities have become complex and patient numbers have declined. For example, in NSCLC there are several oncogenic driver mutations such as ROS1, BRAF, NTRK, EGFR, HER2 and MET, each with their own targeted therapy. At the same time, larger and more sophisticated decision-making tools and associated advanced analysis algorithms help prescribers determine the right treatment for a given patient. In addition to identifying the right treatment, pharmaceutical companies are increasingly offering “white glove” services to assist patients with difficult treatment plans. This is particularly relevant for new cell therapies.FDA approval of CAR-T is expected to increaseFrom two in 2019 to 24 in 2024. These new treatments face challenges in both manufacturing and commercialization. Most assets, including all marketed CAR-Ts and approximately 75% of treatments in development, are autologous, meaning they require costly single-batch production methods. At the same time, only a handful of sites have the appropriate infrastructure and are CAR-T certified, requiring a high-touch business model to bring these emerging therapies to patients, providers, and payers.
Overall, we believe that the oncology therapeutic area will continue to have meaningful and transformative potential for patient outcomes. Significant unmet needs remain in many indications in the United States and worldwide. The potential for innovation is enormous, both in terms of the number of new drugs being tested and investments in the pharmaceutical industry. Precision medicine and new treatments, including cell therapy, have tremendous potential to transform patients' lives. To realize this potential, however, pharmaceutical companies must innovate in ways to shorten development timelines, develop combination therapies, and—crucially—find effective ways to bring those therapies to market.
Bjorn Albrechtis a partner in McKinsey's London office,Simon Alfanois a consultant in the Boston office,Harriet Keaneis an associate partner in the New York office andguangyangis an associate partner in the Charlotte office.
The authors would like to thank Paula del Rey Puech, Tatiana Elphimova, Edd Fleming, Jennifer Gaubatz, Charles Ge, Paul Gurney, Tina Hou, Felix Jede, Eric Koskins, Lucy Pérez, Meredith Reichert, Kate Smietana, Erika Stanzl, and Lydia The for their contributions this post on this article.
Discover careers with us
looking for vacancies
2 Analyst consensus figures indicate a robust 12 percent compound annual growth rate (CAGR), and global oncology therapeutics sales are forecasted to hit $250 billion by 2024. However, there is much more to do.What is the future of the oncology market? ›
New York, April 10, 2023 (GLOBE NEWSWIRE) -- The global oncology market size recorded a valuation of USD 208 billion in 2022 and is expected to reach USD 628 billion by the end of 2032, expanding at a CAGR of 12% over the decade. The term Oncology is the prevention, diagnosis, and treatment of cancer.How big is the oncology market in 2020? ›
According to Precedence Research, the global oncology market size worth at US$ 265.1 billion in 2020 and is predicted to reach over US$ 581.25 billion by 2030.What are the new innovations in oncology? ›
Technologies and innovations like CRISPR, artificial intelligence, telehealth, the Infinium Assay, cryo-electron microscopy, and robotic surgery are helping accelerate progress against cancer.What are the trends in oncology technology? ›
Artificial intelligence (AI), genomic sequencing, and robotics are some technologies that accelerate these innovations. Immunotherapy, cellular, and gene therapies improve the body's response to cancer treatment. Additionally, they advance precision oncology and targeted therapies.What are the drivers of the oncology market? ›
The key drivers of the global oncology/cancer drugs market are surge in geriatric population, surge in prevalence of cancer, early screening of the cancer, and higher number of R&D activities to develop cancer therapeutics have significantly contributed toward the growth of the market.What is the future supply and demand for oncologists? ›
Demand for oncology services is expected to rise rapidly, driven by the aging and growth of the population and improvements in cancer survival rates, at the same time the oncology workforce is aging and retiring in increasing numbers. Demand is expected to rise 48% between 2005 and 2020.What is the outlook for the Mckinsey oncology market? ›
Analyst consensus figures indicate a robust 12 percent compound annual growth rate (CAGR), and global oncology therapeutics sales are forecasted to hit $250 billion by 2024.Is oncology care model going away? ›
The Centers for Medicare & Medicaid Services (CMS) has announced a new, voluntary alternative payment model, which will replace the Oncology Care Model (OCM) that ended on June 30.Who are 21st century oncology competitors? ›
- GenesisCare. Healthcare - Private.
- Aleris. Healthcare - Private.
- Kura Oncology. Healthcare - Public.
- IOP. Healthcare - Private.
- Imbruvica. ...
- Darzalex. Revenues: $8.0 billion. ...
- Opdivo. Revenues: $8.2 billion. ...
- Tagrisso. Revenues: $5.5 billion. ...
- Ibrance. Revenues: $5.1 billion. ...
- Perjeta. Revenues: $4.4 billion. ...
- Tecentriq. Revenues: $4.0 billion. ...
- Pomalyst/Imnovid. Revenues:$3.5 billion.
- Meduit. Healthcare - Private.
- Artera. Healthcare - Private.
- Isabl. Healthcare - Private.
- American HealthTech. Healthcare - Private.
In 2025, Americans newly insured under the ACA will increase the demand by an additional 130 oncologists and five radiation oncologists engaged in FTE clinical care, resulting in a total shortfall of 2,393 clinical care FTEs.How many oncology drugs are in development? ›
There are currently more than 700 oncology drugs in late stages of development.Is oncology a growing field? ›
Industry Spending and Financial Outlook
The oncology market continues to expand at a rapid pace. Experts expect ongoing increases in cancer diagnoses over the next 10 years. Most of these increases will result from an aging population.
There will be substantially more automated and robotic treatment options with fewer radio‐oncology activities, such as delineation, treatment planning, and supervision of radiotherapy delivery, performed by physicians and physicists.
|No. of Pages||250|
|Forecast Period||2022 - 2026|
|Estimated Market Value ( USD ) in 2022||$ 107.81 billion|
The field of oncology has 3 major areas based on treatments: medical oncology, radiation oncology, and surgical oncology.What is an oncology target? ›
Targeted therapy is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. It is the foundation of precision medicine. As researchers learn more about the DNA changes and proteins that drive cancer, they are better able to design treatments that target these proteins.
The oncology workforce shortage poses a significant challenge for all practices, but particularly for nonacademic institutions, according to experts with whom Healio | HemOnc Today spoke.How competitive is oncology specialty? ›
Oncology fellowship programs are highly competitive and require a high level of dedication to attend. Once you've completed your oncology fellowship, you can complete the American Board of Internal Medicine (ABIM) exam for board certification.What motivates oncologists? ›
Oncologists have a deep desire to change the course of the disease for patients with cancer; cure where possible and when a cure is not possible to extend and improve the quality of life remaining and provide effective palliation of symptoms.Are oncologists in high demand? ›
Some cities are flush with oncologists; however, 32 million Americans live in a county with no oncologists. ASCO projects a shortage for more than 2,200 oncologists by 2025.What is the market outlook for oncology in 2023? ›
The market size is anticipated to grow at a CAGR of 7.1% during the forecast period of 2023-2031 to achieve a value of USD 14.3 billion by 2031. Radiation oncology, also known as radiation therapy, is a crucial component of cancer treatment that utilizes high-energy radiation to destroy cancer cells and shrink tumors.What are the highest unmet need cancers? ›
In 2014, we identified brain tumours, and lung, pancreatic and oesophageal cancer as 'cancers of unmet need'.Will BCG overtake McKinsey? ›
BCG is now bigger than McKinsey - quite impressive - their revenue over FTE is better than McKinsey's. Seems that McKinsey's prestige is fading away with all the issues the firm is facing.What is the successor to the oncology care model? ›
The Center for Medicare and Medicaid Innovation (CMMI) is launching a long awaited new oncology model, the Enhancing Oncology Model (EOM). EOM is a successor to the Oncology Care Model (OCM), which ended June 30, 2022 after a five-year demonstration.What is the enhancing oncology model? ›
On June 27, 2022, the Center for Medicare and Medicaid Innovation (CMMI) announced the Enhancing Oncology Model (EOM). 1. The EOM is a voluntary 6-month, 2-sided, risk-based payment model for clinicians caring for Medicare patients with 7 common cancer types beginning on July 1, 2023, for 5 years.Who are US Oncology Network competitors? ›
US Oncology competitors include Genzyme, Pfizer and ac.
AmerisourceBergen Specialty GPOs is the largest specialty group purchasing organization in the oncology field.What happened to 21st century oncology? ›
The sale of 21st Century Oncology (now known as GenesisCare) officially closed today, following customary regulatory reviews. GenesisCare continues to be led by founder and CEO Dan Collins.Who are Elevation Oncology competitors? ›
Who are Elevation Oncology 's competitors? Alternatives and possible competitors to Elevation Oncology may include Resilience , Day One Biopharmaceuticals , and Roivant Sciences .Who is the leading oncology company? ›
As of 2020, Bristol-Myers Squibb (BMS) has once again secured the top position with total revenue of $29.73B, followed by Roche and Merck. Our team at PharmaShots has compiled a list of the top 20 oncology companies based on their 2021 oncology segment revenue.Why do oncology drugs fail? ›
Ultimately, many oncology trials fail because they do not show a treatment extends survival in a meaningful way. For example, a drug tested in ocular melanoma, a rare cancer occurring in the eye, resulted in an eight-week improvement in progression-free survival.How profitable is oncology? ›
Sales Revenue From Cancer Drugs Has Doubled Among Top Pharmaceutical Companies in the Last 10 Years, Exceeding $103 Billion USD in 2019. Key Points: Revenues from the sale of oncology drugs increased by 96% over the past decade, from $52.8 billion USD in 2010 to $103.5 billion USD in 2019.What is the impact factor of clinics in oncology? ›
Clinics in Oncology™ (Impact Factor: 2.709*) and (ISSN 2474-1663) is a peer reviewed open access journal aims to publish basic, translational and clinical original research articles from all areas of Oncology, Clinical Oncology, Surgical Oncology, Radiation Oncology, Medical Oncology, Oncology Case Reports and Images.What is the impact factor of Discovery Oncology? ›
The journal was formerly published as Hormones & Cancer (4.67 2021 Impact Factor). Discover Oncology, formerly Hormones and Cancer, is part of the Discover journal series committed to providing a streamlined submission process, rapid review and publication, and a high level of author service at every stage.What is oncologists impact factor? ›
About Annals of Oncology Impact factor: 32.976.Who bought US Oncology? ›
The McKesson Corporation recently completed its acquisition of US Oncology, a company diligent in its efforts to provide invaluable resources, approaches and increases in the effectiveness of cancer care.
- Amgen (AMGN)
- Bristol-Myers Squibb Company (BMY)
- Five Prime Therapeutics (FPRX)
- Gilead Sciences (GILD)
- Novartis AG ADR (NVS)
- Cardiff Oncology (CRDF)
- Surface Oncology (SURF)
- Trillium Therapeutics (TRIL)
- Cornell University.
- University of California San Francisco.
- University of Toronto.
- Yale University.
- University of California Los Angeles.
- Universite Paris Saclay.
- Vanderbilt University.
- University of Pennsylvania.
New York, April 10, 2023 (GLOBE NEWSWIRE) -- The global oncology market size recorded a valuation of USD 208 billion in 2022 and is expected to reach USD 628 billion by the end of 2032, expanding at a CAGR of 12% over the decade. The term Oncology is the prevention, diagnosis, and treatment of cancer.What is the current oncology market? ›
The global oncology market was valued at US$ 286.04 billion in 2021 and is expected to reach over US$ 581.25 billion by 2030, poised to grow at a noteworthy CAGR of 8.2% from 2022 to 2030.Where do radiation oncologists make the most money? ›
Radiation Oncology Salary Ranges by Location
Radiation oncologists in the Southern region of the United States earn an average of $420,000 per year. The next highest-paying region is the Midwest, with a median average radiation oncology salary of $337,503.
Top 3 drug approvals March 2023: Zynyz®, Calquence®, Keytruda® - Oncology Central.What are the most successful oncology drug portfolios of the past decade? ›
Key examples include Merck's Keytruda, BMS's Opdivo, Pfizer's Ibrance (palbociclib) and AbbVie and Johnson & Johnson's Imbruvica (ibrutinib).What is the global market for oncology drugs? ›
The global oncology drugs market grew from $223.34 billion in 2022, having increased at a compound annual growth rate (CAGR) of 6.5 % since 2017. The market is expected to grow from $223.34 billion in 2022 to $318.31 billion in 2027 at a rate of 7.3 %.What is the market value of oncology? ›
Oncology Market size reached more than USD 280 billion in 2022 and is anticipated to exhibit 9.7% CAGR from 2023-2032. Thriving cancer burden worldwide will drive industry growth.How big is the oncology drug development market? ›
According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
“Cancer is a very, very big and lucrative business for a healthcare organization, particularly if you do it right,” Dubey said.What is the average age of retirement for an oncologist? ›
|Issues addressed:||2013 ||2021|
|When do oncologists tend to retire?||Average age of retirement 65 ||More data required|
|How long do doctors live?||Average age of physician death in the past 20 years is 77 years across all specialties [1, 26]||Average age of death is likely to increase in the future [1, 26]|